Press Release
Copenhagen and Brussels, 04.09.2025
Complimentary business profiles in Belgium provide strong commercial rationale.
Abacus Medicine has signed an agreement to acquire the Retail and Hospital division of the global specialty pharma group A.forall. The division is the market leader within parallel importation in Belgium and sources and distributes a wide range of branded and generic pharmaceutical products to pharmacies, hospitals, and wholesalers across the Benelux region.
The Retail and Hospital division employs approximately 70 people across sites in Belgium and Ireland and generated revenue of approximately EUR 60 million in 2024. Its customer-facing brands include PI Pharma, Impexeco, and Eco.Pharma.Supply.
Frederik Heupel, Chief Commercial Officer for Abacus Medicine, says: “The Retail and Hospital division of A.forall and Abacus Medicine are a perfect match, and we see a great opportunity in combining two business that complement each other well.
The Retail and Hospital division of A.forall has strong, direct relationships with pharmacies, whereas Abacus Medicine primarily serves the pharmacies in Belgium via wholesalers. In addition, Abacus Medicine has a strong focus on high-priced medicine, whereas the Retail and Hospital division of A.forall has a broad range of lower-priced medicine. By joining forces, we can offer our customers great service and access to a broad and attractive product portfolio. “
Gerald Lefèbvre, Chief Operating Officer of Retail and Hospital, says: “The culture and values of our two organizations could not be a better fit. We share an ambition to keep growing to give more people better access to medicine. We are confident that Abacus Medicine is the right, new home for our Retail and Hospital team and activities.”
Commercial potential in combination
The strong commercial rationale behind the combination of the two organizations is based on their highly complementary businesses. The large product portfolio of Retail and Hospital is focused mainly on lower priced medicines and merging this with Abacus Medicine’s portfolio of higher priced, specialty medicines will result in a broader market offering to pharmacies in Belgium and the wider Benelux.
Abacus Medicine Group’s Retail and Hospital will gain access to a superior sourcing network and digital capabilities that will help to further accelerate the growth of the business.
Contact
Peter Høj, Executive Advisor
Mobile: +45 25 54 26 96, peter.hoj@abacusmedicine.com
About Abacus Medicine Group
The Abacus Medicine Group has over 1,500 employees and achieved revenue of EUR 1,500 million in 2024. The Group improves global healthcare by providing better access to medicine and recorded sales in 35 countries globally last year. Recognized for consistently delivering profitable revenue growth, the Group continues to invest in scalable digital excellence and being an employer of choice.
The parallel trade division of the Abacus Medicine Group is among Europe’s leading parallel traders of medicine and the largest European independent distributor of medicine by geographical reach.
For more information, visit: www.abacusmedicine.com and www.abacusmedicinegroup.com
About A.forall
A.forall, previously known as Alter Pharma or the Alter Pharma Group, is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and additional offices in Belgium, Ireland and the United States. Employing in total over 144 employees, the company distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. At the same time, A.forall is a global player on the generics market, with 30+ molecules on the European and U.S. market and a fully stocked pipeline of mainly injectable generics and value-added products covering various therapeutic areas.
For more information, visit: www.aforallpharma.com